Tcr2 Therapeutics - TCRR STOCK NEWS

TCR² Therapeutics Inc. (TCRR) announced an underwritten public offering of 4,590,164 shares at $30.50 per share, totaling gross proceeds of approximately $140 million. There is an option for underwriters to purchase an additional 688,524 shares within 30 days. The offering is slated to close around January 22, 2021. Proceeds will support the company's clinical and early-stage programs, alongside research and development, working capital, and general corporate purposes. The offering is registered under an effective SEC shelf registration.

TCR2 Therapeutics Inc. (Nasdaq: TCRR) has announced an underwritten public offering of $125 million in shares of its common stock, with an option for underwriters to purchase an additional $18.75 million. The proceeds are intended for advancing clinical programs, research and development, and general corporate purposes. The offering is subject to market conditions, and details will be finalized in a prospectus supplement filed with the SEC.

TCR2 Therapeutics (Nasdaq: TCRR) has outlined its strategic priorities for 2021, focusing on advancing its TRuC-T cell therapies. Key milestones include data presentation from the gavo-cel Phase 1/2 trial, identification of the recommended Phase 2 dose, and initiation of the Phase 2 study later this year. Initial data from the TC-110 Phase 1/2 trial is also anticipated. The company maintains a strong cash position of $246.7 million, expected to fund operations into 2023, while continuing to build manufacturing capacity for clinical trials.

TCR² Therapeutics, a clinical-stage immunotherapy company, announced that its CEO Garry Menzel will present an update on company progress at the 39th Annual J.P. Morgan Healthcare Conference on January 14, 2021, at 7:30 AM E.T. The presentation will be held virtually and a live webcast will be available on the company's investors page. TCR² focuses on developing T cell therapies for cancer, including its lead candidates TC-210 and TC-110, targeting solid tumors and hematological malignancies respectively.

TCR² Therapeutics (TCRR) reported promising interim results from its Phase 1 trial of TC-210 (gavo-cel) for mesothelin-expressing solid tumors. All eight patients showed tumor regression, with a 50% overall response rate, including a confirmed partial response in one ovarian cancer patient. Safety remains manageable, with few adverse effects reported. The trial design was amended to accelerate treatment, reducing safety observation periods. A conference call to discuss these results is scheduled for December 14, 2020.

TCR² Therapeutics Inc. (Nasdaq: TCRR) will present interim data from the Phase 1 portion of its TC-210 clinical trial for mesothelin-expressing solid tumors on December 14, 2020. The company will host a conference call and webcast at 8:00 AM ET, which can be accessed via its Investors page. TCR² focuses on innovative T cell therapies, with TC-210 targeting solid tumors and TC-110 aimed at hematological malignancies. These TRuC-T cells demonstrate promising anti-tumor activity in preclinical studies.

TCR2 Therapeutics (TCRR) announced its Q3 2020 financial results and progress in its TC-210 Phase 1/2 clinical trial for cancer therapies. The company reported a net loss of $16.9 million, up from $13.8 million in Q3 2019, largely due to increased personnel expenses. Cash reserves rose to $246.7 million from $158.1 million at the end of 2019. A partnership with ElevateBio aims to enhance manufacturing capabilities for TC-210’s Phase 2 trial. An interim update on the clinical trial is expected in Q4 2020, along with anticipated IND filings for additional TRuC-T cell programs in 2021.

TCR² Therapeutics (Nasdaq: TCRR) has partnered with ElevateBio to enhance manufacturing capabilities for its TC-210 product, aimed at treating various cancers. The collaboration focuses on increasing capacity for the upcoming Phase 2 clinical trial, following observed tumor regression in initial trials. ElevateBio will utilize its advanced facility in Waltham, MA, to support production, complementing TCR²’s existing UK operations. This partnership is expected to meet the anticipated demand for TC-210, a promising T cell therapy targeting mesothelin-expressing cancers.

TCR² Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage immunotherapy company, announced participation in a fireside chat at the Jefferies Cell Therapy Virtual Summit on October 5, 2020, at 2:00 PM E.T. This session will be held virtually, and a live webcast will be available on the company's Investors page. TCR² focuses on developing novel T cell therapies targeting solid tumors and hematological malignancies, with their lead candidates, TC-210 and TC-110, currently in Phase 1/2 clinical trials.